Multiscale Biofluidic and Nanobiotechnology Approaches for Treating Sepsis in Extracorporeal Circuits.
Joo H KangPublished in: Biochip journal (2020)
Infectious diseases and their pandemics periodically attract public interests due to difficulty in treating the patients and the consequent high mortality. Sepsis caused by an imbalanced systemic inflammatory response to infection often leads to organ failure and death. The current therapeutic intervention mainly includes "the sepsis bundles," antibiotics (antibacterial, antiviral, and antifungal), intravenous fluids for resuscitation, and surgery, which have significantly improved the clinical outcomes in past decades; however, the patients with fulminant sepsis are still in desperate need of alternative therapeutic approaches. One of the potential supportive therapies, extracorporeal blood treatment, has emerged and been developed for improving the current therapeutic efficacy. Here, I overview how the treatment of infectious diseases has been assisted with the extracorporeal adjuvant therapy and the potential utility of various nanobiotechnology and microfluidic approaches for developing new auxiliary therapeutic methods.
Keyphrases
- infectious diseases
- septic shock
- acute kidney injury
- intensive care unit
- end stage renal disease
- randomized controlled trial
- ejection fraction
- cardiac arrest
- healthcare
- minimally invasive
- chronic kidney disease
- emergency department
- mental health
- peritoneal dialysis
- high throughput
- low dose
- human health
- high dose
- hepatitis b virus
- single cell
- coronary artery bypass
- climate change
- liver failure
- patient reported outcomes
- replacement therapy
- atrial fibrillation
- smoking cessation
- label free